SCHEMBL4493891

SCHEMBL4493891

COc1ccc(C(C(N)=O)c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.57
CNR2 P34972 2/20 0.56
CNR1 P21554 1/20 0.56
EPHX1 P07099 1/20 0.56
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
KLK7 P49862 3/20 0.51
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
PAX8 Q06710 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
KMT2A Q03164 2/20 0.49
TP53 P04637 1/20 0.49
CYP3A4 P08684 1/20 0.49
MEN1 O00255 1/20 0.49
CA1 P00915 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4507705 0.93 CA1 (0.55) ACP3CNR2CNR1EPHX1NPSR1
SCHEMBL6504793 0.85 ACP3 (0.61) ACP3CNR2CNR1ALDH1A1NPSR1
SCHEMBL1716394 0.85 ACP3 (0.61) ACP3CNR2CNR1ALDH1A1NPSR1
SCHEMBL31362087 0.84 MEN1 (0.45) ACP3CNR2CNR1EPHX1ALDH1A1
SCHEMBL6755554 0.84 ACP3 (0.59) ACP3CNR2CNR1ALDH1A1NPSR1
SCHEMBL741751 0.82 MEN1 (0.58) EPHX1NPSR1L3MBTL1CES2CES1
SCHEMBL5060669 0.82 ACP3 (0.53) ACP3CNR2CNR1EPHX1ALDH1A1
SCHEMBL28833357 0.82 KLK7 (0.62) ACP3CNR2CNR1ALDH1A1NPSR1
SCHEMBL7596731 0.82 ACP3 (0.57) ACP3CNR2CNR1ALDH1A1NPSR1
SCHEMBL2922278 0.81 L3MBTL1 (0.69) ACP3CNR2CNR1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 ACP3 745/4885CNR2 1957/4885CNR1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.